1,633 results on '"dienogest"'
Search Results
2. A Study to Learn More About How Safe Dienogest is and How Well it Works Under Real World Conditions in Indian Women With Endometriosis (VISAGE)
- Published
- 2024
3. "Quick-starting" of a Quadriphasic Contraceptive Pills, 1 - 3 mg Estradiol Valerate/ 2 - 3 mg Dienogest VS 20 mcg Ethinylestradiol/75 mcg Gestodene Focusing on Ovulation Inhibition
- Published
- 2024
4. The Use of Ethinylestradiol/Dienogest in Random Start Rapid Endometrial Preparation
- Author
-
University of Roma La Sapienza and Andrea Etrusco, Principal investigator
- Published
- 2024
5. The Use of Drospirenone/Estetrol, Nomegestrol Acetate/Estradiol and Ethinylestradiol/Dienogest in Random Start Rapid Endometrial Preparation
- Author
-
University of Roma La Sapienza and Andrea Etrusco, M.D.
- Published
- 2024
6. Comparison of the effectiveness of levonorgestrel intrauterine system and dienogest in the management of adenomyosis: A systematic review and meta-analysis.
- Author
-
Akhigbe, R.E., Afolabi, O.A., Adegbola, C.A., Akhigbe, T.M., and Oyedokun, P.A.
- Subjects
- *
LEVONORGESTREL intrauterine contraceptives , *VISUAL analog scale , *WEIGHT gain , *SCIENCE databases , *WEB databases , *PELVIC pain - Abstract
• Dienogest led to a significant reduction in visual analogue scale score compared with the levonorgestrel intrauterine system (LNG-IUS). • Dienogest reduced uterine volume significantly compared with LNG-IUS. • The occurrence of side effects was comparable in the dienogest and LNG-IUS groups. Adenomyosis is a gynaecological lesion that impairs female fertility and contributes to reduced quality of life. There are several surgical and medical options for the management of this lesion; however, women who wish to conceive opt for medical therapies such as the levonorgestrel intrauterine device (LNG-IUS) and dienogest, which have various outcomes. To date, there is no consensus regarding which is more effective. To compare the effectiveness of LNG-IUS and dienogest for the management of adenomyosis, and explore the risk of occurrence of known side effects for both treatments. Design: Systematic review and meta -analysis exploring the effectiveness of LNG-IUS and dienogest for the management of adenomyosis. A literature search was conducted using PICO guidelines and EMBASE, PubMed/MEDLINE, Scopus and Web of Science databases. Only clinical trials were collected and analysed. Of the 792 studies that were initially identified, six were eligible for inclusion in this study. The studies included a total of 707 women; of these, 270 were treated with LNG-IUS, 354 were treated with dienogest, and 83 were controls. All the studies were from Asia (Bangladesh n = 1, China n = 2, India n = 1, Japan n = 1, South Korea n = 1). Dienogest was found to reduce pelvic pain significantly, evidenced by a lower visual analogue scale score, compared with LNG-IUS. Also, dienogest led to a significant reduction in uterine volume compared with LNG-IUS. However, subjects in the LNG-IUS group had significantly higher levels of haemoglobin than those in the dienogest group. Nonetheless, the occurrence of side effects such as weight gain, breast tenderness/distension, headache, insomnia/sleep disorder, depression/mood disorder, skin disorder/acne, and coital discomfort/reduced libido were comparable in both treatment groups. Dienogest may be more effective than LNG-IUS for the management of adenomyosis, as it shows a superior effect in the reduction of pelvic pain and uterine volume. As only six studies were included in the present meta-analysis due to the paucity of data in the literature, it is recommended that well-designed randomized controlled trials comparing the effectiveness of dienogest with LNG-IUS should be conducted. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. A systematic review and Bayesian analysis of the adverse effects of dienogest.
- Author
-
Li, Rui-Rui, Xi, Qing, Tao, Lei, Sheng, Wei, Zhao, Cheng-Cheng, and Wu, Yu-Jie
- Subjects
BONE density ,LUMBAR vertebrae ,PELVIC pain ,UTERINE hemorrhage ,HEMORRHAGIC shock - Abstract
Background and objective: Endometriosis and adenomyosis are two common diseases that impair women's health, and dienogest is one of the pharmacologic treatments which is the first-line therapeutic option for patients with pelvic pain and individuals who have no desire for immediate pregnancy. The goal of this study was to summarize the current evidence of adverse events associated with dienogest as well as the prevalence of these adverse events during treatment with dienogest. Methods: Several databases (PubMed, Embase, Cochrane Central and Clinicaltrials.gov, etc.) and the US FDA Adverse Event Reporting System (FAERS) Public Dashboard were searched on May 31, 2023, using the topic words alongside free words of dienogest and "adverse reaction". Studies were incorporated into this research if they reported or assessed safety issues or adverse reactions of dienogest during the period of endometriosis treatment or adenomyosis therapy. The extracted information comprised trial design, dienogest and control group demographics, as well as reported side effects. Results: This systematic review comprehended 39 publications in total. The mean age of patients in the included studies was 34.43 years. The follow-up duration varied from 3 to 60 months. Most adverse reactions were common and not serious, and the most common adverse reactions during dienogest medication were abnormal uterine bleeding (55%, 95% CI 37–73%), amenorrhea (17%, 95% CI 2–42%) and swelling (13%, 95% CI 3–28%). Uncommon adverse reactions included dysmenorrhea (0.2%, n = 1), dyspepsia (0.4%, n = 1), and (lower) abdominal pain (1%, 95% CI 0–3%), urticaria (1%, 95% CI 0–3%) and peritonitis (1%, n = 1). Serious adverse reactions including decreased lumbar spine Bone Mineral Density (BMD), depression, peritonitis and so on have been reported. Heterogeneity assessment revealed that patient number and study design are influencing factors to adverse reaction prevalence. Moreover, abdominal pain, diarrhea, nausea and vomiting, back pain and anemia are side effects reported both in the FAERS database and in the systematic review. Conclusions: Dienogest's most frequent side effects were not severe. Dienogest is generally safe for treating endometriosis and adenomyosis. Nevertheless, people should be aware of serious adverse reactions, such as decreased lumbar spine BMD and hemorrhagic shock. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Dienogest treatment in women with endometriosis: A retrospective cohort study in Taiwan
- Author
-
Yi-Chieh Chen, Chia-Huang Chang, Ya-Lun Tsai, Ming-Song Tsai, and Li-Ching Chen
- Subjects
Dienogest ,Endometriosis ,CA125 ,VAS ,Taiwan ,Gynecology and obstetrics ,RG1-991 - Abstract
Objective: To assess the treatment efficacy of dienogest specifically in the Taiwanese population with endometriosis. Materials and Methods: Eighty-eight patients diagnosed with endometriosis receiving at least 3 months of dienogest 2 mg once daily, from January 2018 to June 2022, were enrolled. They were divided into two groups: surgery group and non-surgery group. The assessment of pain improvement was based on visual analog scale (VAS) scores (0–100 mm) recorded at 0, 3, 6, and 12 months following the initiation of dienogest. Serum CA-125 value and ovarian endometrioma size were analyzed at 0 and 6 months. Results: A total of 65 patients with endometriosis presented painful symptoms. In the surgery group (N = 28), the initial VAS score was 47.5 mm, which significantly declined to 9.6 mm at 3 months (p
- Published
- 2024
- Full Text
- View/download PDF
9. Association of hemorrhagic shock and pulmonary embolism following the administration of dienogest in a patient diagnosed with adenomyosis
- Author
-
Ihssane Merimi, Lamyae Zinoune, Narjisse Aichouni, Siham Nasri, Imane Skiker, Zakaria Bazid, and Noha Elouafi
- Subjects
Pulmonary embolism ,Hemorrhagic shock ,Dienogest ,Adenomyosis ,Hysterectomy ,Anticoagulation ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
Adenomyosis is a chronic disease associated with abnormal uterine bleeding and debilitating pain with severely reduced quality of life in many affected women. Primary strategies for its management encompass surgical interventions, hormonal therapy, or a synergistic blend of these therapeutic modalities. Dienogest (DNG), a new progestin, is primarily utilized to treat adenomyosis due to its exceptional selectivity for the progesterone receptor. In this uncommon case report, we introduce a 42-year-old woman who experienced hemorrhagic shock as a result of uterine bleeding and pulmonary embolism that occurred while a patient was undergoing dienogest therapy for uterine adenomyosis. This situation necessitated blood transfusion and introduction of drugs then an emergency hysterectomy was scheduled followed by the initiation of anticoagulation. We hypothesize that the emergence of pulmonary embolism was intimately tied to adenomyosis, and the occurrence of hemorrhagic shock was likely due to the intake of dienogest.
- Published
- 2024
- Full Text
- View/download PDF
10. A Study to Learn More About Using Dienogest to Treat Endometriosis in Chinese Participants (VISANNE OS)
- Published
- 2023
11. Comparing the Safety and Efficacy in the Use of Hormonal Therapy on Endometriosis Patients After Conservative Surgery (ENDOSafe)
- Author
-
Yuli Trisetiyono, Principal Investigator
- Published
- 2023
12. A Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, and Tolerability of LPRI-424, 13 Cycles
- Author
-
Chemo Research
- Published
- 2023
13. A Study Run at Multiple Study Sites to Test Whether the SAMANTA Questionnaire That is Used to Diagnose Heavy Menstrual Bleeding (HMB), Can Also be Used to Assess Changes of Severity of HMB in Women With HMB Who Are Treated During 12 Months With a Chronic Hormonal Treatment (SAMIRA)
- Published
- 2023
14. Evaluation of Using Dienogest and N-Acetyl Cysteine on the Volume of Uterine Leiomyoma
- Author
-
Esraa Mosaad Awd El-sayed, Researcher,ob/gyn Resident, Principal Investigator, Esraa Awd
- Published
- 2023
15. CGRP neuropeptide levels in patients with endometriosis-related pain treated with dienogest: a comparative study
- Author
-
Shahla Chaichian, Ziba Dehghan Firoozabadi, Samaneh Rokhgireh, Kobra Tahermanesh, Abolfazl Mehdizadeh Kashi, Azam Govahi, Sara Minaeian, Mehdi Mehdizadeh, and Marziyeh Ajdary
- Subjects
Dienogest ,CGRP ,Pain ,Endometriosis ,Gynecology and obstetrics ,RG1-991 ,Public aspects of medicine ,RA1-1270 - Abstract
Abstract Background and objective Endometriosis (EM) involves the peripheral nervous system and causes chronic pain. Sensory nerves innervating endometriotic lesions contribute to chronic pain and influence the growth phenotype by releasing neurotrophic factors and interacting with nearby immune cells. Calcitonin gene-related peptide (CGRP), a pain-signaling neurotransmitter, has a significant role. This study examines the effect of Dienogest (DNG), a hormone therapy used for managing EM -related pain, on serum CGRP levels in EM patients. Materials and methods The Visual Analog Scale (VAS) assessed pain in diagnosed EM. individuals. Serum samples were obtained to measure CGRP concentration. Participants received a 2 mg/day oral dose of DNG for six months as prescribed treatment. Additional serum samples were collected after this period to measure CGRP levels. Results In the EM group, 6.7%, 33.3%, and 20% had ovarian EM, ovarian plus uterosacral, and ovarian plus bladder, respectively. The EM group showed higher CGRP serum levels than the control group (80.53 ± 16.13 vs. 58.55 ± 6.93, P
- Published
- 2024
- Full Text
- View/download PDF
16. Association between KRAS and PIK3CA Mutations and Progesterone Resistance in Endometriotic Epithelial Cell Line
- Author
-
Kosuke Kanno, Kentaro Nakayama, Sultana Razia, Sohel Hasibul Islam, Zahan Umme Farzana, Shahataj Begum Sonia, Hitomi Yamashita, Masako Ishikawa, Tomoka Ishibashi, Kayo Imamura, Tohru Kiyono, and Satoru Kyo
- Subjects
endometriosis ,progesterone resistance ,KRAS mutation ,dienogest ,Biology (General) ,QH301-705.5 - Abstract
Although endometriosis is a benign disease, it is associated with cancer-related gene mutations, such as KRAS or PIK3CA. Endometriosis is associated with elevated levels of inflammatory factors that cause severe pain. In a previous study, we demonstrated that KRAS or PIK3CA mutations are associated with the activation of cell proliferation, migration, and invasion in a patient-derived immortalized endometriotic cell line, HMOsisEC10. In this study, we investigated the effects of these mutations on progesterone resistance. Since the HMOsisEC10 had suppressed progesterone receptor (PR) expression, we transduced PR-B to HMOsisEc10 cell lines including KRAS mutant and PIK3CA mutant cell lines. We conducted a migration assay, invasion assay, and MTT assay using dienogest and medroxyprogestrone acetate. All cell lines showed progesterone sensitivity with or without mutations. Regarding inflammatory factors, real-time quantitative RT-PCR revealed that the KRAS mutation cell line exhibited no suppression of Cox-2 and mPGES-1 on progesterone treatment, whereas IL-6, MCP-1, VEGF, and CYP19A1 were significantly suppressed by progesterone in both mutated cell lines. Our results suggest that KRAS mutation and PIK3CA mutation in endometriotic cells may not be associated with progesterone resistance in terms of aggressiveness. However, KRAS mutations may be associated with progesterone resistance in the context of pain.
- Published
- 2024
- Full Text
- View/download PDF
17. The effect of dienogest treatment on anti-Mullerian hormone in patients with endometrioma: a 12-month follow-up study.
- Author
-
Karataş, Esra, Temiz, Bilal Esat, Mümüşoğlu, Sezcan, Yaralı, Hakan, and Bozdağ, Gürkan
- Subjects
- *
SEX hormones , *VISUAL analog scale , *DESCRIPTIVE statistics , *ENDOSCOPIC ultrasonography , *ENDOMETRIOSIS , *LONGITUDINAL method , *PAIN , *PROGESTATIONAL hormones , *CONFIDENCE intervals , *PELVIC pain , *OVARIAN reserve - Abstract
Objective: To assess the effect of dienogest treatment on endometrioma (OMA) size, serum anti-Mullerian hormone (AMH) levels and associated pain over a 12-month follow-up period. Material and Methods: A longitudinal cohort study of 104 patients with OMA who were treated with dienogest, between January 2017 and January 2020. Of the included patients, each had a 12-month follow-up period with transvaginal or pelvic ultrasound and measurement of serum AMH concentration at the sixth and twelfth months of follow-up. The alteration in OMA size in the sixth and twelfth months of treatment was the primary outcome measure and the alteration in AMH concentration over the same period was the secondary outcome measure. The only exclusion criterion was having surgical intervention for OMA during the follow-up period (n=44). In patients with bilateral OMA (n=21), the change in size of the largest OMA was considered in the analysis. Results: A total of 60 patients with a mean ± standard deviation (SD) age of 31.5±8.0 years were included. The mean ± SD OMA size on the day the dienogest was started was 46.3±17.4 mm and the mean AMH level was 3.6±2.4 ng/mL. After six months, the mean OMA size had decreased to 38.6±14.0 mm, with a median difference of 7.8 mm [95% confidence interval (CI): 3.0 to 12.6; p=0.003]. The mean AMH level was 3.3±2.7 ng/mL at 6 months follow-up (95% CI: -0.2 to 0.8; p=0.23) and the average difference was 0.3 ng/mL. At the 12th-month visit, when compared with the beginning of the treatment, OMA size had again significantly decreased by a median of -8.9 mm (95% CI: -2.9 to -14.9; p=0.005), and the decline in median AMH was also significant (-0.9 ng/mL, 95% CI: -0.1 to -1.7; p=0.045). The initial mean ± SD visual analog scale pain score at the commencement of dienogest treatment was 6.3±3.4. The mean values at the sixth and twelfth months of dienogest therapy were 1.08±1.8 and 0.75±1.5, respectively (both p<0.001 compared to baseline). Conclusion: At the sixth and twelfth months of dienogest treatment a significant decrease in OMA size and reported pain scores were observed, whereas the AMH concentrations did not change significantly. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. Efficacy and safety of dienogest in the treatment of deep infiltrating endometriosis: A meta-analysis.
- Author
-
Wu, Han, Liu, Jun-Jiang, Ye, Sheng-Tou, Liu, Jun, and Li, Na
- Subjects
- *
ENDOMETRIOSIS , *DYSMENORRHEA , *CONSERVATIVE treatment , *DRUG therapy , *PELVIC pain , *DATABASES - Abstract
• A meta-analysis of conservative treatment of DIE with DNG drugs. • DNG can effectively relieve the pain symptoms related to DIE without resorting to surgical treatment. • DNG showed significantly reducing the size of the lesions when used in the conservative treatment of DIE. To systematically review and conduct a meta-analysis to assess the effectiveness of dienogest (DNG) in the prolonged conservative drug management of deep infiltrating endometriosis (DIE). The findings from this study are intended to serve as a valuable reference for clinical decision-making regarding medication in the context of DIE. Following the PRISMA Statement, we searched EMBASE, PubMed, The Cochrane Library, Web of Science, and Medline databases for relevant literature published in the public domain from the date of establishment of the database until October 2023. Subsequently, all English publications on clinical studies using DNG for the treatment of DIE were included. Studies involving surgical intervention or drug therapy for postoperative recurrence were excluded. All literature included in the review underwent risk assessment of bias. Two evaluators independently screened the publications, conducted a quality assessment of each article and extracted data. We used Revman 5.4 for the meta-analysis of the included literature. Our final analysis consisted of five clinical studies, involving a total of 256 patients. We found that there were significant improvements in the following indicators post-medication as compared to levels before taking the medication: dysmenorrhea (MD = 4.24, 95 % CI: 2.92–5.56, P < 0.00001), non-menstrual pelvic pain (MD = 3.11, 95 % CI: 2.34–3.88, P < 0.00001), dyspareunia (MD = 1.93, 95 % CI: 1.50–2.37, P < 0.00001), dyschezia (MD = 2.48, 95 % CI: 1.83–3.12, P < 0.00001), and rectosigmoid nodule size (MD = 0.32, 95 % CI: 0.18–0.46, P < 0.00001). Compared with pre-medication levels, the following indicators were significantly worse: headache (RR = 0.03, 95 % CI: 0.00–0.23, P = 0.0006), decreased libido (RR = 0.08, 95 % CI: 0.01–0.62, P = 0.02); and there was no significant improvement in dysuria (P > 0.05). DNG showed efficacy in relieving pain-related symptoms and significantly reducing the size of the lesions when used in the drug conservative treatment of DIE. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. ЗАСТОСУВАННЯ СУЧАСНИХ ПРОГЕСТАГЕНІВ У ТЕРАПІЇ ГЕНІТАЛЬНОГО ЕНДОМЕТРІОЗУ.
- Author
-
МАРКІН, Л. Б. and МАТВІЄНКО, О. О.
- Abstract
Analysis of literary data. In total, 41 publications by foreign authors were selected and processed. Information on the effectiveness of the domestic progestogen drug Vigest-KV in the treatment of endometriosis in our own practice is also presented. Today, the newest progestin is dienogest, a derivative of 19-nortestosterone. It has shown its high efficiency in various clinical manifestations of endometriosis, as well as in its recurrences. Long-term treatment regimens with dienogest (60 months) are promising, as they effectively reduce pain and the risk of endometriosis recurrence, in particular after surgical treatment. An important advantage of dienogest is the low frequency of side effects (1.2–2.5%), especially such as the effect on bone mineral density. Our clinical experience allows us to recommend the Ukrainian medicinal product Vigest-KV, containing dienogest, for the treatment of various types of endometriosis. Its advantage is a special mechanism of ovulation blockade aimed at apoptosis of the granulosa cells of the growing follicle. Also, long-term use of this drug leads to the inhibition of follicle-stimulating and luteinizing hormones and a moderate decrease in the estradiol, the level of which is within the physiological parameters. This is very important to avoid the symptoms of estrogen deficiency while maintaining the anti-proliferative effect. Conclusions. Today, the main method of treating endometriosis is hormone therapy. It not only reduces the clinical symptoms of endometriosis, but is also used before and after surgical treatment to reduce the risk of disease recurrence. Progestins (dienogest) are the most common hormonal method of treating endometriosis. Dienogest, as the most effective progestin, has a pronounced anti-proliferative effect directed at the endometrium, as well as anti-inflammatory and immunomodulatory effects with a minimal risk of side effects. Dienogest in a dose of 2 mg/ day provides a reduction in clinical symptoms, an improvement in the quality of life and preservation of reproductive function. Taking into account our own clinical experience of using Vigest-KV in various types of endometriosis, we can recommend its implementation into clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Long-term therapy with dienogest or other oral cyclic estrogen-progestogen can reduce the need for ovarian endometrioma surgery.
- Author
-
Ferrari, Federico, Epis, Matteo, Casarin, Jvan, Bordi, Giulia, Gisone, Emanuele Baldo, Cattelan, Chiara, Rossetti, Diego Oreste, Ciravolo, Giuseppe, Gozzini, Elisa, Conforti, Jacopo, Cromi, Antonella, Laganà, Antonio Simone, Ghezzi, Fabio, and Odicino, Franco
- Subjects
THERAPEUTIC use of progestational hormones ,ESTROGEN replacement therapy ,PEARSON correlation (Statistics) ,BODY mass index ,CHRONIC pain ,T-test (Statistics) ,ANABOLIC steroids ,QUESTIONNAIRES ,INFERTILITY ,FISHER exact test ,ESTROGEN ,TREATMENT effectiveness ,MINIMALLY invasive procedures ,TERTIARY care ,SYMPTOM burden ,DESCRIPTIVE statistics ,MANN Whitney U Test ,CHI-squared test ,ENDOMETRIOSIS ,LONGITUDINAL method ,HUMAN reproductive technology ,RESEARCH ,ANALYSIS of variance ,PROGESTATIONAL hormones ,DYSMENORRHEA ,PELVIC pain ,COMPARATIVE studies ,DATA analysis software ,OVARIAN diseases - Abstract
Background: Almost 10% of women in reproductive age are diagnosed with ovarian endometriomas and can experience symptoms and infertility disorders. Ovarian endometriomas can be treated with medical or surgical therapy. Objective: To assess whether long-term therapy with dienogest or oral cyclic estrogen-progestogens is effective in reducing the size of ovarian endometriomas, alleviating associated symptoms, and reducing the requirement for surgery. Design: Prospective non-interventional cohort study. Methods: We enrolled childbearing women diagnosed with ovarian endometriomas. We collected demographic, clinical, and surgical data, including the evaluation of ovarian endometrioma-associated symptoms and pain using the visual analog scale. We grouped the women according to treatment regimen into dienogest, estrogen-progestogens, and no-treatment. Patient's assessment was performed at baseline and after 12 months evaluating the largest ovarian endometrioma diameter (in millimeters) and the associated symptoms. Furthermore, we analyzed the impact of hormonal treatment in a sub-group of women fulfilling at baseline the criteria for a first-line surgical approach (ovarian endometrioma > 30 mm with visual analog scale > 8 or ovarian endometrioma > 40 mm before assisted reproductive treatments or any ovarian endometrioma(s) > 60 mm). Results: We enrolled 142 patients: 62, 38, and 42 in dienogest, estrogen-progestogens, and no-treatment groups, respectively. No significant differences were found regarding baseline characteristics. After 12 months, the mean largest ovarian endometrioma diameter increased in the no-treatment group (31.1 versus 33.8; p < 0.01), while a significant reduction was registered in the dienogest (35.1 versus 25.8; p < 0.01) and estrogen-progestogens (28.4 versus 16.7; p < 0.01) groups; no significant difference in ovarian endometrioma diameter reduction between these two latter groups was noted (p = 0.18). Ovarian endometrioma-associated symptoms and pain improved in dienogest and estrogen-progestogens groups, with a significantly greater effect for dienogest than for estrogen-progestogens for dysmenorrhea (74% versus 59%; p < 0.01). In the sub-group of women eligible for first-line surgery at baseline, long-term treatment with dienogest and estrogen-progestogens reduced surgical eligibility by 30%. Conclusions: Decreased mean largest ovarian endometriomas'diameter after 12 months and reduction of the need for surgical treatment by 30% were observed in dienogest and estrogen-progestogens groups. Long-term treatment with dienogest had a greater effect in alleviating dysmenorrhea and pain. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Endometriosis: Pathogenesis, diagnosis, treatment and the role of gut microbiota.
- Author
-
Senat, Hanna, Grabowska, Patrycja, Senat, Aleksandra, Bolla, Patrycja, Madej, Aleksandra, Marczyńska, Zuzanna, and Libracka, Karolina
- Subjects
ENDOMETRIOSIS ,GUT microbiome ,DELAYED diagnosis ,CHILDBEARING age ,FECAL microbiota transplantation ,LAPAROSCOPIC surgery - Abstract
Purpose The first aim of this review is to provide an overview of existing literature and current knowledge of endometriosis pathogenesis, diagnosis and recommended forms of treatment. The second aim of this article is to epmhasize the role of the microbiota on the pathogenesis and treatment of endometriosis Endometriosis is a common disease. It affects 5-10% of women of reproductive age worldwide. However, despite its prevalence, diagnosis is typically delayed by years, misdiagnosis is common, and effective treatment takes years to achieve. Determining the mechanisms involved in its pathogenesis is vital, not only to pave the way for early identification, but also for disease management and development of less invasive but successful treatment strategies. Three main types of endometriosis have been described in literature: peritoneal, ovarian and deep infiltrative. This is mainly due to the most common locations of ectopic endometrium. Determining the precise pathogenesis of endometriosis has proved challenging and controversial for gynecologists, endocrinologists and researchers, but recent studies have focused on finding answers. A number of pathogenic mechanisms have been suggested to be involved in the development of endometriosis, and a large number of studies have investigated the causes of its pathogenesis. This disease is often asymptomatic and diagnosed incidentally during various surgical interventions or follow-up gynecological examinations. Women with this pathology report exhaustion and depression, as with other chronic pain conditions. However, the severity of pain doesn't always reflect the severity of endometriosis. Epidemiological research reports that women with this disease are more vulnerable to ovarian and breast cancer, asthma, skin cancer such as melanoma, cardiovascular disease and inflammatory joint diseases like rheumatoid arthritis. Due to the lack of specific symptoms diagnosis is often delayed about 6-10 years from the first symptoms. According to current gynecological recommendations, the clinical examination of patients with a suspicion of endometriosis should include inspection and palpation of the abdominal cavity, vaginal speculum, vaginal vault and a two-handed gynecological examination, best complemented by a composite study. Nowadays, geneticists are in complete agreement about the primary goals of endometriosis treatment. The most important of these are the relief or complete elimination of pain, the removal of endometriosis foci, and the fight against fertility. To date, the most commonly used therapy is combination therapy, which consists of surgical procedures such as laparoscopy, laparotomy, or cryosurgery, and adjuvant hormonal therapy, which has significantly reduced the risk of recurrence The microbiota is a diverse ecosystem of microorganisms that reside in various parts of the human organism. Specific microbiomes can be distinguished for the oral cavity, nasal cavity, ears, vagina, gastrointestinal tract, respiratory system, hair and skin. The connection between the gut microbiota and endometriosis is nowadays highly suspected to exist. Scientists are focused on the influence of the microbiome on estrogens, estrogens-dependent disorders, immune system, and inflammation. It is strongly believed that the correction of the gut microbiota with antibiotics, probiotics, or fecal bacterial transplantation is a hopeful method for improving the clinical management of endometriosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. CGRP neuropeptide levels in patients with endometriosis-related pain treated with dienogest: a comparative study.
- Author
-
Chaichian, Shahla, Firoozabadi, Ziba Dehghan, Rokhgireh, Samaneh, Tahermanesh, Kobra, Kashi, Abolfazl Mehdizadeh, Govahi, Azam, Minaeian, Sara, Mehdizadeh, Mehdi, and Ajdary, Marziyeh
- Subjects
- *
PELVIC pain , *CALCITONIN gene-related peptide , *PERIPHERAL nervous system , *PAIN management , *VISUAL analog scale , *HORMONE therapy - Abstract
Background and objective: Endometriosis (EM) involves the peripheral nervous system and causes chronic pain. Sensory nerves innervating endometriotic lesions contribute to chronic pain and influence the growth phenotype by releasing neurotrophic factors and interacting with nearby immune cells. Calcitonin gene-related peptide (CGRP), a pain-signaling neurotransmitter, has a significant role. This study examines the effect of Dienogest (DNG), a hormone therapy used for managing EM -related pain, on serum CGRP levels in EM patients. Materials and methods: The Visual Analog Scale (VAS) assessed pain in diagnosed EM. individuals. Serum samples were obtained to measure CGRP concentration. Participants received a 2 mg/day oral dose of DNG for six months as prescribed treatment. Additional serum samples were collected after this period to measure CGRP levels. Results: In the EM group, 6.7%, 33.3%, and 20% had ovarian EM, ovarian plus uterosacral, and ovarian plus bladder, respectively. The EM group showed higher CGRP serum levels than the control group (80.53 ± 16.13 vs. 58.55 ± 6.93, P < 0.0001). Still, after drug administration, CGRP serum levels significantly decreased compared to pre-treatment levels (69.66 ± 11.53 vs. 80.53 ± 16.13, P < 0.05). The EM group showed higher pain compared to the control group (7.93 ± 1.58 vs. 0.13 ± 0.35, P < 0.0001), but after drug administration, pain significantly decreased compared to pre-treatment levels (1.00 ± 2.00 vs. 7.93 ± 1.58, P < 0.05). Conclusion: DNG administration reduces pain and serum CGRP levels in EM patients, offering the potential for innovative treatments and tailored options. Understanding neurotransmitter roles and drug effects can aid in discovering more effective modulators for these pathways. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. The effects of dienogest and combined oral contraceptives on protein S-specific activity in endometriosis patients.
- Author
-
Yokota, Natsuko, Inoue, Reiko, Kawamura, Keiko, Egashira, Katsuko, Kuma, Hiroyuki, and Kato, Kiyoko
- Subjects
- *
ORAL contraceptives , *PROTEIN S deficiency , *PROTEIN S , *VENOUS thrombosis , *ENDOMETRIOSIS - Abstract
• Protein S-specific activity didn't change significantly during hormonal treatments. • Protein S activity and antigen levels decreased soon with oral contraceptives. • Protein S activity and antigen levels didn't decrease with dienogest. • 4 out of 111 patients were suspected of having protein S deficiency. One serious side effect of combined oral contraceptives (COCs) is venous thromboembolism. Reduced activity in activated protein C-related coagulation pathways is attributable to low protein S activity in one-third of Japanese patients with deep vein thrombosis. Herer, we quantified the behavior of protein S-specific activity in response to dienogest (DNG) and COCs using the protein S-specific activity assay system to explore its potential utility as a thrombosis marker. This was a prospective cohort study. Female patients aged 20 – 49 years who were starting drug treatment for endometriosis using DNG or COCs were enrolled. Blood samples were taken before treatment and at the first, third, and sixth months of treatment. To analyze the primary endpoints, changes in total protein S antigen levels, total protein S activity, and protein S-specific activity from baseline to each time point were estimated using a linear mixed-effects model. All statistical analyses were performed in the SAS software version 9.4 (SAS Institute, Cary, NC). A two-sided P < 0.05 was considered statistically significant. 64 patients took DNG and 34 patients took COCs. Protein S-specific activity did not change significantly from baseline in the six months after treatment started in either group. In the DNG group, total protein S activity and total protein S antigen levels increased slightly from baseline levels after the treatment. The means for total protein S activity and total protein S antigen levels in the COC group remained within reference limits, but they both decreased markedly in the first month and stayed low. Protein S-specific activity in four women remaind below the reference limit throughout the whole study period, suggesting they may have potential protein S deficiencies. The effects of DNG on protein S were negligible, though both total protein S activity and antigen levels decreased soon after COC treatment began and remained low. As there was no VTE event during the study, further studies with larger numbers of patients will be needed to confirm that protein S-specific activity can be a surrogate maker of VTE risk. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. A Study to Gather Information About User Satisfaction in Women in Russia Who Take Estradiol Valerate/Dienogest (Q-SWAN)
- Published
- 2023
25. The Effect of Dienogest vs. Norethindrone Acetate Treatment in Endometriosis (DINE)
- Author
-
GÜRKAN UNCU,PROF. MD, Professor
- Published
- 2023
26. Adenomyosis and ART (ADENOFERT)
- Author
-
University of Modena and Reggio Emilia, Ministero della Salute, Italy, and Fabio Facchinetti, Head of Obstetrics and Gynecology at the University Hospital unimore
- Published
- 2023
27. Synthetic vs Natural Estrogen in Combined Oral Contraception (SYLVI)
- Author
-
Oulu University Hospital and Annina Haverinen, MD
- Published
- 2023
28. Effect of Management of the Endometrioma on Ovarian Reserve (IMTERO)
- Author
-
Hospital Comarcal Francesc de Borja Gandía, Valencia, Spain, Hospital Universitario San Juan de Alicante, Poznan University of Medical Sciences, and Antonio Cano Sanchez, Professor Obstetrics & Gynecology
- Published
- 2023
29. Evaluation of the therapeutic efficacy of high-intensity focused ultrasound ablation combined with different drugs in the treatment of adenomyosis
- Author
-
Yu Dai, Ling Liu, Guiyuan Yu, Yan Peng, Na Chen, Jiahong Gao, Qiuling Shi, and Ping Jin
- Subjects
Adenomyosis ,high-intensity focused ultrasound ,dienogest ,GnRH-a ,LNG-IUS ,Medical technology ,R855-855.5 - Abstract
Objectives To observe the therapeutic efficacy of high-intensity focused ultrasound (HIFU) combined with different pharmacological treatments for adenomyosis.Materials and methods A total of 126 patients with adenomyosis who underwent HIFU combined with pharmacological treatment were retrospectively reviewed. Patients were treated with either dienogest (DNG) (Group A, N = 38) or GnRH-a (Group B, N = 88) for three months after HIFU, and received levonorgestrel-releasing intrauterine systems (LNG-IUS) at the end of the third month. Visual Analog Scale (VAS) and Pictorial Blood Loss Assessment Chart (PBAC) scores were used for evaluating symptom improvement.Results After propensity score matching (1:2), 38 patients were included in Group A and 76 in Group B. All patients showed significant improvement in VAS and PBAC scores after HIFU, but the PBAC score of Group A was significantly higher than that of patients in Group B at 18 months [11.50 (1.00, 29.50) vs. 0.00 (0.00, 16.50), p
- Published
- 2024
- Full Text
- View/download PDF
30. Long-term treatment for endometriosis with dienogest: efficacy, side effects and tolerability
- Author
-
Francesco La Torre, Silvia Vannuccini, Federico Toscano, Ernesto Gallucci, Gretha Orlandi, Virginia Manzi, and Felice Petraglia
- Subjects
Endometriosis ,dienogest ,long-term treatment ,chronic pelvic pain ,tolerability ,Gynecology and obstetrics ,RG1-991 ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
AbstractBackground Dienogest (DNG) improves endometriosis-associated pain (EAP) and patients’ quality of life; however, the modern cornerstone of the management of endometriosis is the long-term adherence of the patient to medical treatment.Objective To evaluate DNG as a long-term treatment of endometriosis, focusing on patients’ compliance and side effects, also correlating with different phenotypes of endometriosis.Methods This was a cohort study on a group of patients with endometriosis (n = 114) undergoing long-term treatment with DNG. During the follow up visits (12, 24, and 36 months) patients were interviewed: an assessment of EAP was performed by using a visual analogue scale (VAS) and side effects were evaluated by using a specific questionnaire of 15 items.Results At 12 months, 81% were continuing the DNG treatment, with a significant reduction of dysmenorrhea, dyspareunia, dyschezia, dysuria and chronic pelvic pain. Of the 19% that discontinued the treatment: 62% was due to spotting, reduced sexual drive, vaginal dryness, and mood disorders. The improvement of EAP was significant for all endometriosis phenotypes, especially in patients with the deep infiltrating type. At 36 months, 73% of patients were continuing the treatment, showing a significant reduction of EAP through the follow up, along with an increase of amenorrhea (from 77% at 12 months to 93% at 36 months). In a subgroup of 18 patients with gastrointestinal disorders, DNG was administered vaginally at the same dosage, showing similar results in terms of efficacy and tolerability.Conclusions DNG was an effective long-term treatment for all endometriosis phenotypes, with few side effects that caused the discontinuation of the treatment mainly during the first year. Thus, the course of 1-year treatment is a predictive indicator for long-term treatment adherence.
- Published
- 2024
- Full Text
- View/download PDF
31. Comprehensive management of umbilical endometriosis using a unique laparoscopic entry portal (Darwish point) and postoperative dienogest.
- Author
-
Darwish, Atef, Darwish, Dina AM, Fathi, Mohamed, and Elmahdi, Hoda
- Subjects
- *
ENDOMETRIOSIS , *LAPAROSCOPIC surgery , *NAVEL , *SURGICAL excision - Abstract
Umbilical endometriosis, although relatively rare, has been described with plenty of case reports and case series available in the literature. Surgical excision has been the preferred mode of treatment, with or without excision of the umbilicus. Few cases described laparoscopically assisted excision but lacked descriptions of a safe alternative non-umbilical laparoscopy entry portal, management of possible concomitant intraperitoneal lesions, and aesthetic umbilicus repair. The aim of this work is to describe a modified technique of laparoscopically assisted excision of umbilical endometriosis and treat concomitant intraperitoneal lesions via a new laparoscopic entry portal with aesthetic preservation of the umbilicus. Successful complete excision of the mass with aesthetic preservation of the umbilicus followed by 3 months of Dienogest therapy resulted in complete resolution of the mass. It is concluded that utilizing "Darwish point" for abdominal access to excise umbilical endometriosis and treat concomitant intraabdominal lesions, offers smart abdominal access with aesthetic umbilicus repair. Moreover, postoperative hormonal treatment (Dienogest) is helpful to ensure a better cure. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
32. Dienogest attenuates STAT3 activation in ovarian endometriotic cysts.
- Author
-
Choi, JongYeob, Jo, MinWha, Lee, EunYoung, Kim, Sung Eun, Lee, Dong-Yun, and Choi, DooSeok
- Subjects
- *
STAT proteins , *OVARIAN cysts , *STROMAL cells , *CELL proliferation , *PROLIFERATING cell nuclear antigen - Abstract
Recent studies have suggested that endometriosis could be the result of excessive activation of signal transducer and activator of transcription 3 (STAT3), which is associated with the regulation of essential cellular mechanisms such as proliferation, invasion, and apoptosis. That finding implies that regulating STAT3 activation could play a key role in treating endometriosis. In the present study, we aimed to evaluate whether the anti-endometriotic effects of dienogest is mediated by the regulation of STAT3 activation. STAT3 activation was evaluated in normal endometrial and ovarian endometriotic tissues obtained from patients with/without preoperative dienogest treatment. A subsequent in vitro analysis with endometriotic cyst stromal cells (ECSCs) was used to confirm the direct influence of dienogest in STAT3 activation. STAT3 activation is significantly higher in endometriotic tissues from non-treated patients than in normal endometrial tissues, and that difference is reversed by preoperative administration of dienogest. Similarly, the inhibitory effects of dienogest on STAT3 activation are demonstrated by in vitro results showing that dienogest treatment significantly inhibits IL-6-stimulated STAT3 activation in cultured ECSCs. That inhibition was accompanied by decreased expression of proliferative (PCNA), invasive (MMP-2), and anti-apoptotic (BCL-2) proteins. Furthermore, downregulating STAT3 activity with siRNA decreased PCNA, MMP-2, and BCL-2 expression in IL-6-treated ECSCs. Dienogest inhibits STAT3 activation in ECSCs, which affects their proliferation, invasiveness, and apoptosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. Medikamentöse Therapie der Endometriose.
- Author
-
Burghaus, Stefanie and Beckmann, Matthias W.
- Abstract
Copyright of Die Gynäkologie is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2024
- Full Text
- View/download PDF
34. The Effect of Rubus idaeus Polyphenols Extract in Induced Endometriosis in Rats.
- Author
-
Jianu, Elena-Mihaela, Pop, Raluca Maria, Gherman, Luciana Mădălina, Ranga, Floricuța, Levai, Antonia-Mihaela, Rus, Vasile, Bolboacă, Sorana D., Ștefan, Roxana-Adelina, Onofrei, Mădălin Mihai, Nati, Ionel-Daniel, Stoia, Ioana Alexandra, Ștefan, Paul-Andrei, Mihu, Carina, and Mihu, Carmen Mihaela
- Subjects
- *
ENDOMETRIOSIS , *RUBUS , *TRANSFORMING growth factors-beta , *AUTOGRAFTS , *WEIGHT gain , *POLYPHENOLS - Abstract
Endometriosis is a common gynecological condition with a complex physio-pathological background. This study aimed to assess the role of Rubus idaeus leaf extract (RiDE) as a potential therapeutic agent in reducing the size of the endometriotic lesions and modulate the plasma expression of MMP-2, MMP-9, and TGF-β1. The endometriotic lesions were induced in a rat model by the autologous transplant of endometrium. Thirty-six female rats, Wistar breed, with induced endometriosis, were divided into four groups and underwent treatment for 28 days. The CTRL group received 0.5 mL/day of the vehicle; the DG group received 1 mg/kg b.w./day dienogest; the RiDG group received 0.25 mL/kg b.w./day RiDE and the D+RiDG group received 1 mg/kg b.w./day dienogest and 0.25 mL/kg b.w./day RiDE, respectively. Rats' weight, endometriotic lesion diameter and grade, and plasma levels of MMP-2, MMP-9, and TGF-β1 were assessed before and after treatment. The administration of RiDE in association with dienogest vs. dienogest determined a lower weight gain and a reduction in diameter of the endometriotic lesions. RiDE administration restored MMP2 and MMP9 plasma levels to initial conditions. Rubus idaeus extract may help in reducing dienogest-associated weight gain, lower the size of endometriotic lesions, and have anti-inflammatory effects through MMP2 and MMP9 reduction. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
35. Case report: Malignant transformation of ovarian endometrioma during long term use of dienogest in a young lady.
- Author
-
Yi-Ting Chang, Ting-Fang Lu, Lou Sun, Yu-Hsiang Shih, Shih-Tien Hsu, Chin-Ku Liu, Sheau-Feng Hwang, and Chien-Hsing Lu
- Subjects
ENDOMETRIOSIS ,OOCYTE retrieval ,FERTILITY preservation ,ADJUVANT chemotherapy ,DISEASE relapse - Abstract
Endometriosis is a benign disease, which is also regarded as a precursor to ovarian malignancy. Dienogest is a progestin treatment for endometriosis with efficacy and tolerability. A 35-year-old Taiwanese lady with ovarian endometrioma had taken dienogest for the last 5 years. During sonographic follow-up, surgery was suggested owing to suspicious of malignant transformation of ovarian endometrioma. While she hesitated and turned to receive two cycles of oocyte retrieval because of nulliparity. Meanwhile, more papillary growth in the ovarian endometrioma with intratumor flow was found during follow-up. Laparoscopic enucleation was performed later, and pathology revealed clear cell carcinoma with peritoneal involvement, at least FIGO stage IIB. She then underwent debulking surgery to grossly no residual tumor and received adjuvant chemotherapy with no tumor recurrence in post-operative 17-months follow-up. Considering fertility preservation, conservative treatment of ovarian endometrioma is typically indicated for those women who have not yet completed childbearing. However, malignant transformation may still occur despite long-term progestin treatment. Therefore, careful image follow-up is still indispensable. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. A Bioequivalence Trial of Dienogest in Healthy Chinese Participants Under Fed Conditions.
- Author
-
Zhao, Chunyan, Wang, Yuxia, and Shao, Yanhua
- Abstract
This trial was a randomized, open‐label, single‐dose, 2‐treatment, 2‐period, crossover study to evaluate the pharmacokinetic (PK) profile, bioequivalence, and safety of test formulation and reference formulation of 2‐mg dienogest tablets in healthy Chinese participants. Eligible participants were randomly administered a single 2‐mg dose of either the test formulation or the reference formulation orally under fed conditions, followed by a 1‐week washout period and the administration of the other formulation. Samples of blood were collected until 48 hours following administration. The main PK parameters were calculated using noncompartmental analysis techniques. The main PK parameters included maximum plasma concentration, area under the plasma concentration–time curve (AUC) from time zero to the last quantifiable concentration, and AUC from time zero to infinity. The bioequivalence of test and reference dienogest tablets was determined if the 90% confidence intervals of the geometric mean ratio of the test to reference formulations were within the predefined range of 80%‐125%. The safety assessment included incidence of adverse events and serious adverse events and others. Twenty‐four healthy Chinese participants were enrolled in this trial. The geometric mean ratios of maximum plasma concentration, AUC from time zero to the last quantifiable concentration, and AUC from time zero to infinity between the 2 formulations, and corresponding 90% confidence intervals, all fell within the range of 80%‐125% under fed conditions. The test and reference dienogest tablets were well tolerated, and no severe adverse events were reported in the trial. It was shown that the test and the reference dienogest tablets were bioequivalent and well tolerated under fed conditions in healthy Chinese female participants. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. Comparison of efficacy between levonorgestrel intrauterine system and dienogest in adenomyosis: a randomized clinical trial.
- Author
-
Choudhury, Satish, Jena, Saubhagya Kumar, Mitra, Subarna, Padhy, Biswa Mohan, and Mohakud, Sudipta
- Subjects
- *
DRUG efficacy , *ENDOMETRIOSIS , *PAIN , *ANDROGENS , *INTRAUTERINE contraceptives , *LEVONORGESTREL , *RANDOMIZED controlled trials , *PRE-tests & post-tests , *COMPARATIVE studies , *TREATMENT effectiveness , *T-test (Statistics) , *METRORRHAGIA , *QUALITY of life , *DESCRIPTIVE statistics , *QUESTIONNAIRES , *CHI-squared test , *PROGESTATIONAL hormones , *STATISTICAL sampling , *DRUG side effects , *DATA analysis software , *PATIENT safety , *PAIN management , *EVALUATION - Abstract
Background: Medical management of adenomyosis is an emerging perspective in modern gynecology. Though levonorgestrel intrauterine system (LNG-IUS) and dienogest (DNG) effectively relieve symptoms in adenomyosis, neither has been approved for the same indication. Our study aims to compare the efficacy and safety of these progestins in treating adenomyosis. Objective: To study the efficacy and safety of LNG-IUS versus DNG in patients with symptomatic adenomyosis. Design: Open-labeled, parallel, single-centered, randomized clinical trial. Methods: Patients with adenomyosis-associated pain with or without abnormal uterine bleeding were randomly allocated to either LNG-IUS group or DNG group. The primary outcome was a reduction in painful symptoms after 12 weeks of treatment measured by visual analog scale (VAS) score. Changes in menstrual blood loss (MBL), improvement in quality of life (QoL), and adverse drug reactions were also analyzed. Results: The VAS score significantly decreased from baseline in both groups. The baseline and post-treatment VAS scores in the LNG-IUS group were 6.41 ± 1.07 and 3.41 ± 1.04 (p = <0.001) and in the DNG group, were 6.41 ± 0.95 and 3.12 ± 1.40 (p = <0.001), respectively. A significantly greater proportion of patients in the LNG-IUS group experienced lighter MBL as compared to the DNG group [27/30 (90%) in the LNG-IUS group versus 17/22 (77.2%) in the DNG group (p = 0.006)]. Both the groups had improvement in QOL scores calculated by the World Heath Organisation QOL scale (WHOQOL BREF) questionnaire; however, it was more pronounced in the DNG group [(28.76 ± 30.47 in the LNG-IUS group versus 48.26 ± 44.91 in the DNG group (p = 0.04)]. Both the agents were safe as there were no reported major adverse drug reactions. Conclusion: DNG can be an effective and safe alternative to LNG-IUS for the medical management of adenomyosis. Trial registration: The trial was prospectively registered at the clinical trial registry – India (CTRI) vide CTRI number CTRI/2020/05/025186. Plain language summary: Comparison of effectiveness and safety of Mirena (LNG-IUS) with dienogest for treatment of adenomyosis Adenomyosis is a condition affecting women, typically aged 40–50, but its incidence is rising in younger women, impacting fertility. It causes painful symptoms like dysmenorrhea, dyspareunia, chronic pelvic pain, and heavy menstrual bleeding. Managing symptoms is crucial, and medical approaches include levonorgestrel intrauterine system (LNG-IUS) and dienogest (DNG). LNG-IUS is reversible contraception, approved for eight years, effectively treating symptoms. DNG, a newer progestin, is effective for endometriosis, but evidence for adenomyosis is limited. This single-center, open-label randomized clinical trial compared LNG-IUS and DNG in treating adenomyosis. Women over 20 with pelvic pain were diagnosed using ultrasound and met specific criteria. After informed consent, participants were assigned randomly to LNG-IUS or DNG groups. Treatment outcomes, including pelvic pain, quality of life (QoL), and adverse effects, were assessed over 12 weeks. Out of 84 assessed, 74 women were recruited, with 34 in each group analyzed. After 12 weeks, both groups showed significantly reduced pelvic pain (VAS scores), but no significant difference was found between the groups. LNG-IUS resulted in a significantly greater reduction in heavy menstrual bleeding (HMB), whereas DNG showed better improvement in overall QOL. Adverse effects were similar in both groups, with hot flushes reported in the DNG group. This study is one of the few comparing LNG-IUS and DNG for adenomyosis, finding both effective for symptom relief. Although LNG-IUS was superior in reducing HMB, DNG showed better overall improvement in QoL. Safety profiles were similar. Previous studies support the efficacy of DNG in reducing adenomyosis symptoms. To conclude, both LNG-IUS and DNG effectively alleviate adenomyosis symptoms, with LNG-IUS superior in reducing heavy menstrual bleeding and DNG showing better overall improvement in QOL. DNG is a viable and effective alternative to LNG-IUS. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. Combined Surgical and Hormonal Approach as a Treatment Option for Deep Endometriosis.
- Author
-
Skhirtladze, D., Kristesashvili, J., and Charekishvili, R.
- Subjects
TREATMENT of endometriosis ,PELVIC pain ,EPIDEMIOLOGY ,MEDLINE - Abstract
Background: Deep endometriosis represents a chronic, progressive disease, frequently characterized by pelvic pain and infertility. Although laparoscopic surgery is the mainstay of treatment for severe endometriosis-associated pain or failed medical therapy, post-surgical management of the disease still remains a subject of discussion. As for infertility treatment, the effectiveness of surgical intervention remains controversial due to the lack of robust trials. Few existing studies suggest that the use of selective progestin-dienogest may have a positive effect on improving endometriosis-associated pain, fertility rate and in-vitro outcomes. A possible improvement in the prognosis may be attributed to the positive effect of dienogest on the eutopic endometrium, which is structurally altered in endometriosis. Therefore, it has become reasonable to include hormonal therapy for the effective management of endometriosis after surgical intervention. Aim: We aimed to observe the available literature data to weigh prospects of combined surgical and medical therapy for more effective management of endometriosis. To bring more insights into better understanding the challenges associated with endometriosis treatment, epidemiology, classification systems, pathogenesis along with current treatment options were reviewed. Methods: For this purpose, the following electronic databases were searched: PubMed, Medline, Scopus, Cochrane Library, Web of Science, WES, Science Direct, NCBI, National Library of Medicine, Springer. Results: Overall, 120 articles, expert recommendations and practice committee options were reviewed, 59 of them displayed certain degree of statistical significance. They were analyzed and discussed in our article. Conclusion: After literature review, it has become more obvious that existing research data are mostly heterogeneous and inconclusive; therefore, the majority of study findings can't be generalized. Research data is limited to accurately analyze and determine the timing and duration of optimal hormonal therapy after surgery for deep endometriosis. Further studies are needed to address the challenges of effective management of endometriosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
39. Comparisons of the Therapeutic Effects of Dienogest and Danazol on Endometriosis
- Author
-
Sheng-Mou Hsiao, Chief, Department of Obstetrics & Gynecology
- Published
- 2023
40. Dienogest in Perimenopausal Women With Adenomyosis
- Published
- 2023
41. The Effect of Dionegest Use on the Frequency of Fibromyalgia in Endometriosis
- Author
-
Fatma Ketenci Gencer, MD, Principal investigator
- Published
- 2023
42. Risk factors of heavy uterine bleeding in patients with endometriosis and adenomyosis treated with dienogest
- Author
-
Hiroaki Takagi, Masahiro Takakura, and Toshiyuki Sasagawa
- Subjects
Dienogest ,Endometriosis ,Adenomyosis ,Uterine fibroma ,Uterine bleeding ,Gynecology and obstetrics ,RG1-991 - Abstract
Objective: Dienogest (DNG), a fourth-generation progestin, reduces pain associated with endometriosis and uterine adenomyosis; however, it is associated with irregular uterine bleeding that can cause anemia and poor quality of life. We investigated risk factors for heavy bleeding following DNG administration. Materials and methods: We retrospectively investigated patients who received DNG for risk factors of heavy uterine bleeding, including clinical diagnosis, use of pretreatment gonadotropin-releasing hormone agonist, smoking, cancer antigen 125, and blood hormone levels. We additionally assessed the uterine area in patients with uterine adenomyosis, the major axis of the uterine body, the major axis of myometrial thickness, the site of tumor development, and the site of myoma development in patients with uterine fibroids. Results: Eighty Japanese patients were administered DNG. The median age was 41 (range: 24–51) years. The odds ratio (OR) for moderate-to-severe bleeding according to clinical diagnosis were 0.33 (P = 0.011) for endometrioma and 9.00 (P = 0.049) for uterine adenomyosis. Receiver operating characteristic curve analysis of the uterine area associated with uterine adenomyosis showed an area under the curve (AUC) of 0.909 between those with major and minor bleeding, with an optimal cut-off value of 7388.2 mm2. The uterine body major axis had an AUC of 0.946, with an optimal cut-off value of 78.3 mm. The major axis of myometrial thickness had an AUC of 0.855, with an optimal cut-off value of 46.8 mm. Conclusion: Patients with endometrioma treated with DNG were less likely to experience heavy uterine bleeding. Uterine bleeding in patients with uterine adenomyosis and adenomyosis associated with uterine fibroids should be closely monitored while administering DNG.
- Published
- 2023
- Full Text
- View/download PDF
43. Chronic pelvic pain in endometriosis: from therapeutic Abstraction to clinical definition: A review
- Author
-
Mekan R. Orazov, Viktor E. Radzinski, and Evgeny D. Dolgov
- Subjects
endometriosis ,chronic pelvic pain ,dienogest ,Gynecology and obstetrics ,RG1-991 - Abstract
Currently, endometriosis is one of the most common and relevant gynecological conditions. It is characterized by a wide range of symptoms, with highly heterogeneous pain being one of the most typical. The unifying concept of the algological patterns of endometriosis is chronic pelvic pain, which contributes to a pronounced decrease in patients' quality of life. Therefore, it is necessary to analyze the key pathogenetic mechanisms of pelvic pain associated with endometriosis and to determine a personalized therapeutic approach based on them.
- Published
- 2023
- Full Text
- View/download PDF
44. Dienogest in endometriosis treatment: A narrative literature review.
- Author
-
Joowon Lee, Hyeon Ji Park, and Kyong Wook Yi
- Subjects
- *
PELVIC pain , *DYSMENORRHEA , *LITERATURE reviews , *ENDOMETRIOSIS , *CHILDBEARING age , *THERAPEUTICS , *EMBRYO implantation - Abstract
Endometriosis is characterized by the implantation of endometrial cells outside the uterus. This hormone-dependent disease is highly prevalent among women of reproductive age. Clinical symptoms of endometriosis include dysmenorrhea, pelvic pain, and infertility, which can negatively impact the overall quality of life of those affected. The medical treatment of endometriosis serves as an important therapeutic option, aimed at alleviating pain associated with the condition and suppressing the growth of endometriotic lesions. As such, it is employed as an adjuvant therapy following surgery or an empirical treatment after the clinical diagnosis of endometriosis. Dienogest, a fourth-generation progestin, has received approval for the treatment of endometriosis in many countries. A growing body of evidence has demonstrated its efficacy in managing endometriosis-associated pain, preventing symptoms, and reducing lesion recurrence. In this review, we examine the clinical efficacy, safety, and tolerability of dienogest in treating endometriosis. We also provide updated findings, drawing from clinical studies that focus on the long-term use of this medication in patients with endometriosis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
45. Possible Participation of Adenine Nucleotide Translocase ANT1 in the Cytotoxic Action of Progestins, Glucocorticoids, and Diclofenac on Tumor Cells.
- Author
-
Ulchenko, Darya, Miloykovich, Lilia, Zemlyanaya, Olga, Shimanovsky, Nikolay, and Fedotcheva, Tatiana
- Subjects
- *
PROGESTATIONAL hormones , *DICLOFENAC , *GLUCOCORTICOIDS , *MEDROXYPROGESTERONE , *ADENINE - Abstract
A comparative analysis of the cytostatic effects of progestins (gestobutanoyl, megestrol acetate, amol, dienogest, and medroxyprogesterone acetate), glucocorticoids (hydrocortisone, dexamethasone), and diclofenac on tumor cells was carried out in order to confirm their in silico predicted probabilities experimentally. The results showed the different sensitivity of HeLa, MCF-7, Hep-2, K-562, and Wi-38 cell lines to progestins, glucocorticoids, and diclofenac. The minimum IC50 was found for progestin gestobutanoyl (GB) as 18 µM for HeLa cells, and varied from 31 to 38 µM for MCF-7, Hep-2, and K-562. Glucocorticoids and diclofenac were much less cytotoxic in the HeLa, MCF-7, and Hep-2 cell lines than progestins, with IC50 values in the range of 150–3000 μM. Myelogenous leukemia K-562 cells were the least sensitive to the action of progestins and glucocorticoids but the most sensitive to diclofenac, which showed a pronounced cytotoxic effect with an IC50 of 31 μM. As we have shown earlier, progestins can uniquely modulate MPTP opening via the binding of adenine nucleotide translocase. On this basis, we evaluated the expression of adenylate nucleotide translocase ANT1 (SLC25 A4) as a possible participant in cytotoxic action in these cell lines after 48 h incubation with drugs. The results showed that progestins differently regulated ANT1 expression in different cell lines. Gestobutanoyl had the opposite effect on ANT1 expression in the HeLa, K562, and Wi-38 cells compared with the other progestins. It increased the ANT1 expression more than twofold in the HeLa and K562 cells but had no influence on the Wi-38 cells. Glucocorticoids and diclofenac increased ANT1 expression in the Wi-38 cells and decreased it in the K562, MCF-7, and Hep-2 cells. The modulation of ANT1 expression discovered in our study can be a new explanation of the cytotoxic and cytoprotective effects of hormones, which can vary depending on the cell type. ANT isoforms in normal and cancerous cells could be a new target for steroid hormone and anti-inflammatory drug action. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
46. Risk of Venous Thromboembolism from Use of Dienogest: Experimental Study on Rats.
- Author
-
Alsarraje, Hadeel Anwer and Alhyali, Liqaa Khalel
- Subjects
- *
THROMBOEMBOLISM , *FEMORAL vein , *LUNGS , *POISONS , *ESTRUS , *RATS , *PNEUMONIA - Abstract
Background and objective: We aimed to identify the effects of dienogest on inducing thromboembolism in rats following exposure to dienogest for a period of either 10 days (2 estrus cycles), 20 days (4 estrous cycles), or 30 days (6 estrus cycles). Materials and Methods: To do so, 40 rats were divided into 4 groups; dienogest-free control group, dienogest treated for 10 days (G1), 20 days (G2), and 30 days (G3). Then lungs and femoral veins were collected from subjects after sacrificing them, and these tissues were fixed for histological analysis. Results: Results showed that venous thromboembolism increased with dienogest therapy as indicated by the increased score of inflammation in the lung tissues, alongside increased thickness of femoral vein wall, and histological findings of fibrin deposition, vessel congestion, inflammatory cells infiltrations, and epithelial desquamation. Conclusion: To sum up, dienogest long-term therapy could be a risk for cardiac thrombotic diseases, and therefore we do advise using alternative progesterone or adding estrogen in low doses to minimize toxic effects primarily when used as postmenopausal replacement therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
47. The Efficacy of Dienogest in Reducing Disease and Pain Recurrence After Endometriosis Surgery: a Systematic Review and Meta-Analysis.
- Author
-
Muzii, Ludovico, Di Tucci, Chiara, Galati, Giulia, Carbone, Fabiana, Palaia, Innocenza, Bogani, Giorgio, Perniola, Giorgia, Tomao, Federica, Kontopantelis, Evangelos, and Di Donato, Violante
- Abstract
The objective of this study is to determine whether dienogest therapy after endometriosis surgery reduces the risk of recurrence compared with placebo or alternative treatments (GnRH agonist, other progestins, and estro-progestins). The design used in this study is systematic review with meta-analysis. The data source includes PubMed and EMBASE searched up to March 2022. A systematic review and meta-analysis were performed in accordance with guidelines from the Cochrane Collaboration. Keywords such as "dienogest," "endometriosis surgery," "endometriosis treatment," and "endometriosis medical therapy" were used to identify relevant studies. The primary outcome was recurrence of endometriosis after surgery. The secondary outcome was pain recurrence. An additional analysis focused on comparing side effects between groups. Nine studies were eligible, including a total of 1668 patients. At primary analysis, dienogest significantly reduced the rate of cyst recurrence compared with placebo (p < 0.0001). In 191 patients, the rate of cyst recurrence comparing dienogest vs GnRHa was evaluated, but no statistically significant difference was reported. In the secondary analysis, a trend toward reduction of pain at 6 months was reported in patients treated with dienogest over placebo, with each study reporting a significantly higher reduction of pain after dienogest treatment. In terms of side effects, dienogest treatment compared with GnRHa significantly increased the rate of spotting (p = 0.0007) and weight gain (p = 0.03), but it was associated with a lower rate of hot flashes (p = 0.0006) and a trend to lower incidence of vaginal dryness. Dienogest is superior to placebo and similar to GnRHa in decreasing rate of recurrence after endometriosis surgery. A significantly higher reduction of pain after dienogest compared with placebo was reported in two separate studies, whereas a trend toward reduction of pain at 6 months was evident at meta-analysis. Dienogest treatment compared with GnRHa was associated with a lower rate of hot flashes and a trend to lower incidence of vaginal dryness. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
48. Compare the Efficacy of Dienogest and the Levonorgestrel Intrauterine System in Women with Adenomyosis.
- Author
-
Guo, Weina, Lin, Yuchen, Hu, Sijian, and Shen, Yi
- Published
- 2023
- Full Text
- View/download PDF
49. BIOCHEMICAL AND HISTOLOGICAL CHANGES IN REPRODUCTIVE ORGANS OF EXPERIMENTAL RATS AFTER DIENOGEST THERAPY.
- Author
-
Alsarraje, Hadeel Anwer, Alhyali, Liqaa Khalel, and Aldabbagh, Ehsan Hassan
- Subjects
ENDOMETRIOSIS ,FEMALE reproductive organs ,FALLOPIAN tubes ,TRIGLYCERIDES ,LIVER enzymes - Abstract
The precise method of action of dienogest on the production and development of endometriosis lesions is unknown, and its controversial effect on endometrial thickness has been under investigation. In the following study the Dienogest's effects on the target animal's histology of female reproductive organs, including the tissues from the Fallopian tubes, ovaries, and uterus, as well as the impact of drug administration on the liver's enzymes and the drug's effects on triglycerides, body weight, and HbA1c, have all been studied. The findings of the following experiment indicated that there was no significant elevation of liver enzymes. The little to no elevation of the liver enzymes indicated that the drug did not induce stress on the hepatic cells and according to the subsequent experiment it is safe for clinical use. Moreover, after 10, 20, and 30 days of blood administration, the level of blood TG significantly decreased, and after 30 days of intake, the level of blood sugar significantly decreased. However, there were no appreciable changes after 10 and 20 days. After 30 days of treatment, the rats' weight also showed a very minor drop. In addition to it, the results of histological changes in the tissue in the following study represented that there were evident changes in the tissues which comprised of decline in blood circulation, fibrosis in tissues, and degeneration of follicles. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
50. 'Always trendy'. Neoclassic, or favorite endometriosis localizations
- Author
-
Mekan R. Orazov, Viktor E. Radzinskii, and Evgenii D. Dolgov
- Subjects
endometriosis ,superficial peritoneal endometriosis ,cystic ovarian endometriosis ,deeply infiltrative endometriosis ,surgical treatment ,dienogest ,coc ,Internal medicine ,RC31-1245 - Abstract
Endometriosis continues to be an unsolved/unsolvable problem of modern gynecology. There are only 3 most common clinical phenotypes of this disorder: superficial peritoneal endometriosis, cystic ovarian endometriosis and deeply infiltrative endometriosis. In view of significantly reduced quality of life in patients with endometriosis resulting from algological symptoms and endometriosis-associated infertility, it is necessary to consider the features of clinical management of a patient with the “favorite” endometriosis localization to provide effective clinical management and improve the therapy efficacy.
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.